The five strongest signals for elranatamab included increased c-reactive protein (N = 5, ROR = 10.29), uveitis (N = 4, ROR = 13.79), decreased red blood cell count (N = 4, ROR = 9.02), cellulitis (N = 3, ROR = 5.06) and respiratory failure (N = 3, ROR = 4.10). Here, CRP is linked to cellulitis.